IPO Boutique

Aktis Oncology, Inc. IPO Advisory

Share this IPO Profile:

Smart Search
Company begins with...
Company contains...

For IPO Boutique's "scale of 1 to 5" BUY rating on Aktis Oncology, Inc., and our comprehensive analysis, click "Buy Market Research".
Company
Symbol
Price Range
Issue Price
Open
Shares
Trade Date
Aktis Oncology, Inc.AKTS -
NASDAQ
$16.00-$18.00 $18.00 $27.0017.65 million1/9/2026
J.P. Morgan, BofA Securities, Leerink Partners, TD Cowen
Co-Manager(s):
Health Care
Filing(s):

Filed 2025-12-19
Terms Added 2026-01-05



Aktis Oncology, Inc. Quote & Chart - Click for current quote - AKTS

About Aktis Oncology, Inc. (adapted from Aktis Oncology, Inc. prospectus):
They are a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies..

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.



IPO Boutique aggregates information on public companies and private companies, such as "AKTS" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.

Used our Comprehensive Single Promo Advisory and want more?
We also offer a monthly or annual subscription






© 2005 - 2026 IPO Boutique. All Rights Reserved